Trial Outcomes & Findings for Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) (NCT NCT00595231)
NCT ID: NCT00595231
Last Updated: 2019-02-27
Results Overview
The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.
COMPLETED
PHASE2
239 participants
8 Weeks
2019-02-27
Participant Flow
A total of 239 subjects were randomized into the trial from 19 of the 20 study sites initiated.
Participant milestones
| Measure |
Rufinamide
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
0 mg. tablet
|
|---|---|---|
|
Overall Study
STARTED
|
120
|
119
|
|
Overall Study
COMPLETED
|
115
|
114
|
|
Overall Study
NOT COMPLETED
|
5
|
5
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Baseline characteristics by cohort
| Measure |
Rufinamide
n=115 Participants
500 mg for 1 week followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
Total
n=229 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
38.4 years
STANDARD_DEVIATION 12.47 • n=99 Participants
|
35.6 years
STANDARD_DEVIATION 11.53 • n=107 Participants
|
37.0 years
STANDARD_DEVIATION 12.07 • n=206 Participants
|
|
Sex: Female, Male
Female
|
76 Participants
n=99 Participants
|
81 Participants
n=107 Participants
|
157 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
39 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
72 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
12 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
31 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
103 Participants
n=99 Participants
|
95 Participants
n=107 Participants
|
198 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
12 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
14 Participants
n=99 Participants
|
17 Participants
n=107 Participants
|
31 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
82 Participants
n=99 Participants
|
69 Participants
n=107 Participants
|
151 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
7 Participants
n=99 Participants
|
18 Participants
n=107 Participants
|
25 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
115 participants
n=99 Participants
|
114 participants
n=107 Participants
|
229 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 8 WeeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Screening
|
25.5 score on a scale
Standard Deviation 3.70
|
25.6 score on a scale
Standard Deviation 3.77
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 1
|
21.9 score on a scale
Standard Deviation 6.04
|
21.4 score on a scale
Standard Deviation 5.71
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 2
|
20.0 score on a scale
Standard Deviation 6.29
|
19.6 score on a scale
Standard Deviation 5.97
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 3
|
18.0 score on a scale
Standard Deviation 7.45
|
17.8 score on a scale
Standard Deviation 7.02
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Baseline
|
25.5 score on a scale
Standard Deviation 3.77
|
25.8 score on a scale
Standard Deviation 3.74
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 6
|
15.7 score on a scale
Standard Deviation 7.34
|
16.7 score on a scale
Standard Deviation 7.32
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 8
|
15.1 score on a scale
Standard Deviation 7.76
|
15.1 score on a scale
Standard Deviation 7.19
|
|
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Last Observation
|
16.7 score on a scale
Standard Deviation 7.91
|
16.1 score on a scale
Standard Deviation 7.65
|
PRIMARY outcome
Timeframe: 8 WeeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 1
|
-0.2 score on a scale
Standard Deviation 2.66
|
-0.1 score on a scale
Standard Deviation 2.02
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 6
|
-1.4 score on a scale
Standard Deviation 3.57
|
-1.2 score on a scale
Standard Deviation 3.20
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 8
|
-2.0 score on a scale
Standard Deviation 3.61
|
-1.6 score on a scale
Standard Deviation 3.07
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Last Observation
|
-1.2 score on a scale
Standard Deviation 3.74
|
-1.4 score on a scale
Standard Deviation 3.01
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 2
|
-0.4 score on a scale
Standard Deviation 2.42
|
-0.4 score on a scale
Standard Deviation 2.69
|
|
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 3
|
-1.0 score on a scale
Standard Deviation 3.14
|
-0.5 score on a scale
Standard Deviation 2.91
|
PRIMARY outcome
Timeframe: 8 WeeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.
|
15.7 score on a scale
Standard Deviation 5.51
|
16.4 score on a scale
Standard Deviation 4.86
|
PRIMARY outcome
Timeframe: 8 weeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)
|
4.5 score on a scale
Standard Deviation 0.60
|
4.4 score on a scale
Standard Deviation 0.56
|
PRIMARY outcome
Timeframe: 8 weeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline Raskin Depression Scale.
|
5.2 score on a scale
Standard Deviation 1.22
|
5.3 score on a scale
Standard Deviation 1.20
|
PRIMARY outcome
Timeframe: 8 weeksPopulation: ITT Population: Randomized and received at least one dose of the study drugs.
The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.
Outcome measures
| Measure |
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
|
Placebo
n=114 Participants
Placebo, 0 mg tablets
|
|---|---|---|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Baseline
|
10.7 score on a scale
Standard Deviation 1.35
|
10.6 score on a scale
Standard Deviation 1.33
|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 3
|
8.3 score on a scale
Standard Deviation 2.51
|
8.1 score on a scale
Standard Deviation 1.99
|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Screening
|
10.7 score on a scale
Standard Deviation 1.39
|
10.5 score on a scale
Standard Deviation 1.26
|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 6
|
7.5 score on a scale
Standard Deviation 2.51
|
7.6 score on a scale
Standard Deviation 2.21
|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 8
|
7.1 score on a scale
Standard Deviation 2.50
|
7.4 score on a scale
Standard Deviation 2.17
|
|
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Last Observation
|
7.7 score on a scale
Standard Deviation 2.73
|
7.7 score on a scale
Standard Deviation 2.29
|
Adverse Events
Rufinamide
Placebo
Serious adverse events
| Measure |
Rufinamide
n=115 participants at risk
500 mg for 1 week followed by 1000 mg for 7 weeks
|
Placebo
n=114 participants at risk
0 mg tablet
|
|---|---|---|
|
Infections and infestations
Acute Bronchitis
|
0.87%
1/115 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Pregnancy, puerperium and perinatal conditions
Ecotopic Pregnancy
|
0.00%
0/115 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.88%
1/114 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
Other adverse events
| Measure |
Rufinamide
n=115 participants at risk
500 mg for 1 week followed by 1000 mg for 7 weeks
|
Placebo
n=114 participants at risk
0 mg tablet
|
|---|---|---|
|
Eye disorders
Vision Blurred
|
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Abdominal pain
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Constipation
|
7.0%
8/115 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.88%
1/114 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Diarrhoea
|
2.6%
3/115 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
3.5%
4/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Dry Mouth
|
5.2%
6/115 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
4.4%
5/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Dyspepsia
|
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Nausea
|
8.7%
10/115 • Number of events 12 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
10.5%
12/114 • Number of events 13 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Gastrointestinal disorders
Vomiting
|
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
2.6%
3/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
General disorders
Fatigue
|
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
4.4%
5/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Infections and infestations
Upper respiratory tract infection
|
6.1%
7/115 • Number of events 7 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
7.9%
9/114 • Number of events 11 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Infections and infestations
Urinary tract infection
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Injury, poisoning and procedural complications
Joint sprain
|
0.00%
0/115 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Metabolism and nutrition disorders
Increased appetite
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Musculoskeletal and connective tissue disorders
Athralgia
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
1.8%
2/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Nervous system disorders
Dizziness
|
5.2%
6/115 • Number of events 7 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
6.1%
7/114 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Nervous system disorders
Headache
|
12.2%
14/115 • Number of events 16 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
19.3%
22/114 • Number of events 24 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Nervous system disorders
Sedation
|
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.88%
1/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Nervous system disorders
Somnolence
|
10.4%
12/115 • Number of events 12 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
8.8%
10/114 • Number of events 10 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Psychiatric disorders
Anxiety
|
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
3.5%
4/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Psychiatric disorders
Insomnia
|
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
3.5%
4/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
|
Skin and subcutaneous tissue disorders
Rash
|
4.3%
5/115 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
|
Additional Information
Christopher Kenney, Senior Vice President - Medical Affairs
Acorda Therapeutics
Results disclosure agreements
- Principal investigator is a sponsor employee The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.
- Publication restrictions are in place
Restriction type: OTHER